Form 4: CalciMedica CEO Reports Stock Option Grant

CalciMedica CEO Rachel Leheny reports the grant of employee stock options, with vesting contingent on an S-8 filing.

Summary

• Rachel Leheny, CEO of CalciMedica, Inc., has reported a transaction related to her beneficial ownership of company stock.
• The transaction involves the grant of an employee stock option with an exercise price of $0.585.
• A total of 148,482 shares are subject to this option.
• Vesting of these shares is scheduled to begin on April 1, 2026, with 1/48th vesting monthly over four years.
• However, vesting is contingent upon the company filing a registration statement on Form S-8 for the shares.
• These shares were automatically added to the authorized issuance under the company's 2023 Equity Incentive Plan on January 1, 2026, due to an annual 'evergreen' provision.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on an executive stock option grant with a delayed vesting condition, rather than providing new financial or strategic performance data.

Positives

• The CEO has been granted stock options, indicating continued incentive alignment with the company's performance.
• The option grant provides a potential upside for the CEO if the company's stock price increases above the exercise price.
• The 'evergreen' provision in the equity plan allows for automatic replenishment of authorized shares, supporting future equity grants.

Negatives

• Vesting of the stock options is delayed and contingent on a future S-8 filing, introducing uncertainty.
• The earliest vesting date is April 1, 2026, which is a significant time away.
• The filing does not provide details on the company's financial performance or operational status, which are crucial for assessing the value of the options.

Risks

• The primary risk is the delay in vesting, which is dependent on the company's ability to file the Form S-8 registration statement.
• Failure to file the S-8 could prevent the options from vesting as planned.
• The value of the options is subject to market fluctuations and the company's future stock performance.
• The 'evergreen' provision, while beneficial for future grants, could lead to dilution if not managed carefully.

Future Outlook

Vesting of the reported stock options is contingent on the company filing a Form S-8 registration statement, with the earliest vesting date set for April 1, 2026, and monthly installments over four years thereafter.

Management Comments

• Vesting is contingent upon the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual 'evergreen' provision.

Industry Context

StockSavvy.ai notes that the issuance of stock options to key executives is a common practice in the biotechnology and pharmaceutical sectors, aiming to retain talent and align incentives with long-term value creation. The contingent vesting based on regulatory filings is also typical for companies navigating the complexities of public offerings and equity plan administration.

Stakeholder Impact

• Shareholders: The stock option grant, while standard, represents potential future dilution. The delay in vesting introduces uncertainty regarding executive compensation realization.
• Employees: The 'evergreen' provision in the equity plan supports future employee stock grants, but the specific conditions for this CEO grant highlight potential administrative hurdles.
• Management: The CEO's compensation is tied to future company performance and regulatory compliance, as evidenced by the contingent vesting.

Next Steps

• CalciMedica must file the Form S-8 registration statement to enable the vesting of the reported stock options.
• The company will need to monitor the monthly vesting of the options beginning April 1, 2026, provided the S-8 filing is completed.

Key Dates

Keywords

Form 4, SEC Filing, CalciMedica, CALC, Stock Options, Employee Stock Option, Beneficial Ownership, Vesting Schedule, Equity Incentive Plan, Rachel Leheny, CEO, Insider Trading